Replies to post #281726 on Anavex Life Sciences Corp (AVXL)

[georgejjl]

The ANAVEX®2-73 (blarcamesine) U.S. Phase 2 study enrolled 31 patients with Rett syndrome and all patients completed the 7-week trial.

https://www.anavex.com/anavex-life-sciences-announces-completion-of-anavex2-73-blarcamesine-u-s-phase-2-rett-syndrome-clinical-trial/

Anavex Life Sciences Announces Achievement of Enrollment Target for the ANAVEX®2-73 (blarcamesine) Phase 2 Parkinson’s Disease Dementia (PDD) Clinical Trial

http://www.anavex.com/anavex-life-sciences-announces-achievement-of-enrollment-target-for-the-anavex2-73-blarcamesine-phase-2-parkinsons-disease-dementia-pdd-clinical-trial/

GOD bless,

[ExtremelyBullishZig]

I agree...wow! That was really difficult for me to write...but it felt good.

"The ANAVEX®2-73 (blarcamesine) U.S. Phase 2 study enrolled 31 patients with Rett syndrome and all patients completed the 7-week trial."